期刊文献+

肺炎克雷伯杆菌对氟喹诺酮类抗生素耐药机制的研究 被引量:13

The mechanism of resistance of Klebsiella pneumoniae to Fluoroquinolones
下载PDF
导出
摘要 目的研究临床分离的耐氟喹诺酮类药物肺炎克雷伯杆菌的耐药机制。方法临床分离、鉴定的肺炎克雷伯杆菌采用琼脂二倍稀释法测定氟喹诺酮的MIC,从中选取10株耐氟喹诺酮的菌株。通过聚合酶链反应(PCR)扩增gyrA基因和parC基因,扩增产物片段长度分别为625、319bp,经纯化后测序。用琼脂二倍稀释的方法测定5种氟喹诺酮类单独使用及与泵抑制剂CCCP合用后的MIC。结果5株耐氟喹诺酮肺炎克雷伯杆菌的gyrA和parC基因经测序分析,显示gyrA的第83位(TCC→ATC/TTG)均出现了突变,引起了相应氨基酸的改变(Ser-83→Ile/Leu)。其中有一株同时也出现了第87位点(GAC→AAC)的改变,氨基酸也由Asp→Asn。parC有4株出现了第80位点突变(AGC→ATC),引起氨基酸由Ser→Ile的改变。MIC测定结果显示,有一株肺炎克雷伯杆菌在单用5种氟喹诺酮类药物及与CCCP合用后,MIC降低了8~32倍;两株肺炎克雷伯杆菌分别对环丙沙星及左氧氟沙星所测的MIC降低了32倍和4倍;还有一株对左氧氟沙星和司帕沙星在使用CCCP前后的MIC降低了4倍。结论gyrA和parC基因突变是肺炎克雷杆菌对氟喹诺酮类产生耐药机制的主要原因,主动外排机制也是肺炎克雷伯杆菌耐氟喹诺酮类抗生素的因素之一。 OBJECTIVE To study the mechanism of resistance of Klebsiella pneumoniae to Fluoroquinolones. METHODS 10 fluoroquinolone- resistance clinical isolates were collected. Their region of gyrA and parC genes were amplified by polymerase chain reaction (PCR), the PCR products(625 bp and 319 bp respectively) were purified and directly sequenced. Minimal inhibitory concentrations (MIC) of 5 FQNs with and without CCCP were determined by the agar dilution method. When the MICs of FQNs with CCCP decreased 4 times or less than the MICs of FQNs without CCCP, it indicated existence of efflux mechanism. RESULTS The results by DNA sequencing showed that the all strains had an TCC→ATC or TCC→TTG mutation in codon 83, leading to amino acid change: Ser→Leu or Ser→Ile. At the same. time , a GAC→AAC mutation was found in codon 87 which resulted in amino acid change:Asp→Asn. Furthermore, DNA sequencing analysis of pails also revealed point mutation (AGC→ATC) leading the substitution of a Ile for Set in 4 strains. As for the MICs, there was one strain that the MICs of the 5 Fluoroquinolones with CCCP decreased 8 to 32 times than the MICs without CCCP. The MICs of Ciprofloxacin and Levofloxacin with CCCP was 32 times and 4 times lower than the MICs without CCCP for the other two strains, respectively. MICs of another isolate to Levofloxacin and sparfloxacin with CCCP decreased 4 times than without CCCP. CONCLUSION The mutation of gyrA and parC gene are the primary mechanisms responsing for resistance of Klebsiela pneumoniae to FQNs, and efflux is also an important factor.
出处 《华西药学杂志》 CAS CSCD 北大核心 2006年第1期21-24,共4页 West China Journal of Pharmaceutical Sciences
关键词 肺炎克雷伯杆菌 氟喹诺酮 耐药机制 聚合酶链反应 最低抑菌浓度 Klebsiella pneumoniae Fluoroquinolones Resistance mechanism PCR MIC
  • 相关文献

参考文献11

  • 1马越,李景云,姚蕾,张力,胡昌勤,金少鸿.1999-2003年广东和辽宁地区大肠埃希菌和肺炎克雷伯菌临床分离株耐药性比较分析[J].临床药物治疗杂志,2005,3(2):46-52. 被引量:6
  • 2National Committee ibr Clinical Laboratory Standard. Performance standards for antimicrobial susceptibility testing[M]. Fourteenth informational Supplement,2004.
  • 3Valdezate S, Vindel A, Echeita A, et al. Topiosomerase Ⅱ and Ⅳ quinolone resistance - determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility[J]. Antimicrob Agents Chemother, 2002,46: 665.
  • 4Hooper DC. Becterial topiosomerase, anti- topoiserases and anti-topoiserases resistance[J]. Clin Infect Dis, 1998,27(supp Ⅱ):S54.
  • 5王重振,钱利生.细菌对喹诺酮类抗菌药的分子耐药机制[J].中国生物工程杂志,2003,23(12):26-30. 被引量:13
  • 6Yoshida H, Bogaki M, Nakamura M et al. Quinolone resistance- determining region in the DNA gyrase gyrA gene of Eacherichia coli[J].Antimicrob Agents Chemother, 1990,34:1271.
  • 7刘啸,张书利.曲伐沙星的化学、生物学性质[J].国外医药(抗生素分册),1998,19(4):306-310. 被引量:20
  • 8Schneiders T, Arnyes SG, Levy SB. Role of AcrR and RamA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore[J]. Antimicrob Agents Chemother,2003,47:2831.
  • 9Deguchi T, Kawamura T, Yasuda M, et al. In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urimary tract infections [J]. Antimicrob Agents Chemother, 1997,41: 1609.
  • 10Brisse S, D Milatovic, A C Fluit, et al. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin and trovafloxacin against Klebsiella pneumoniae, Klebsiella oaytoca,Enterobacter cloacae and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins [J]. Antimicrob Agents Chemother, 1999,43: 2051.

二级参考文献9

  • 1[1]Bopp CA,Brenner FW,Wells JG,et al . Escherichia,Shigella,and Salmonella In Murray P R,Baron EJ,Pfalier MA,et al.Mannual of Clinical microbiology.7th ed.American society for microbiology,Washington,D.C:1999,459~474
  • 2[2]National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing.12th inform suppl.M2-A7 and M7-A5.National Committee for Clinical Laboratory Standards,Wayne,pa 2003
  • 3[5]Domenech-Sanchez A,Pascual A,Suarez AI et al.Activity of nine antimicrobial agents against clinical isolates of Escherichia coli producing extended-spectrum-lactamases and deficient or not in porins.J Antimicrob Chemother,2000, 46: 858~860
  • 4[9]Oliver A,Perez-Diaz JC,Coque TM,et al. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing-lactamase(CTX-M-10)isolated in Spain.Antimocrob Agents Chemother,2001,245,616~620
  • 5[10]Oteo J,Campos J,Baquero F,et al.Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in European Antimicrobial Resistance Surveillance System(2001). J Antimocrob Chemother,2002,50,945~952
  • 6Anne-Béatrice Blanc-Potard,Eloi Gari,Flavia Spirito,Nara Figueroa-Bossi,Lionello Bossi. RNA polymerase (rpoB) mutants selected for increased resistance to gyrase inhibitors in Salmonella typhimurium[J] 1995,MGG Molecular & General Genetics(6):680~692
  • 7王辉,吴伟元,陈民钧.肠杆菌科细菌中超广谱β-内酰胺酶(ESBL)的研究[J].中华微生物学和免疫学杂志,2001,21(6):676-679. 被引量:100
  • 8陈鸿波,马越,李景云,姚蕾,张力,胡昌勤,金少鸿.中国50家医院1994—2000年环丙沙星耐药性的变迁[J].中国抗感染化疗杂志,2002,2(1):43-45. 被引量:29
  • 9佘丹阳,刘又宁.AmpC酶和超广谱β-内酰胺酶在阴沟肠杆菌中的表达及对其耐药性的影响[J].中华医学杂志,2002,82(19):1355-1358. 被引量:86

共引文献34

同被引文献157

引证文献13

二级引证文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部